Gene · 200576
Papers1,790
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 1,790
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Apilimod in oncology: From non-malignant origins to emerging anti-cancer potential. | Eur J Pharmacol | 2026 | 42067017 | PubTator, text mining | PubMed |
| Phosphate adaptive regulation in microalgae from phosphorus-rich livestock wastewater: Enhanced metabolic pathways contrasting with impaired transport. | Bioresour Technol | 2026 | 42044851 | PubTator, text mining | PubMed |
| Metabolic Salvage and Acyl-chain Remodeling Support Glycosphingolipid Synthesis within the PDAC Tumor Microenvironment. | bioRxiv | 2026 | 42039671 | PubTator, text mining | PubMed |
| Phosphoinositide kinase PIKfyve inhibitor apilimod blocks hepatitis E virus infection. | eGastroenterology | 2026 | 41948149 | PubTator, text mining | PubMed |
| Targeting IP6 signaling to destabilize homologous recombination proteins to overcome PARP inhibitor resistance. | Nat Commun | 2026 | 41935081 | PubTator, text mining | PubMed |
| Polypharmacologic phosphoinositide modulation by FTY720 triggers endomembrane trafficking collapse and metabolic starvation in cancer cells. | Biochem Biophys Res Commun | 2026 | 41924780 | PubTator, text mining | PubMed |
| Targeting the ferritinophagy-lysosome axis as a therapeutic vulnerability in gastroenteropancreatic neuroendocrine tumors. | Cell Rep Med | 2026 | 41881024 | PubTator, text mining | PubMed |
| Structure-based calculation of excipient effects on the viscosity of concentrated antibody solutions. | MAbs | 2026 | 41863436 | PubTator, text mining | PubMed |
| Targeting GRB2 with Polyphyllin H overcomes PIKFYVE inhibitor resistance in bladder cancer by blocking Akt-SREBP1-SCD1 pathway. | Phytomedicine | 2026 | 41795291 | PubTator, text mining | PubMed |
| Unraveling GDAP1: Bridging Mitochondrial Biology and Peripheral Neuropathy. | Biomolecules | 2026 | 41750352 | PubTator, text mining | PubMed |
| A cell line development vector strategy for improved expression of a trispecific T-cell engager in CHO. | MAbs | 2026 | 41749074 | PubTator, text mining | PubMed |
| CRISPR screening redefines therapeutic target identification and drug discovery with precision and scalability. | J Pharm Anal | 2026 | 41732321 | PubTator, text mining | PubMed |
| Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB): A Translational Pharmacodynamic Biomarker for PIKfyve Inhibition With VRG50635. | Clin Transl Sci | 2026 | 41708347 | PubTator, text mining | PubMed |
| Novel Substituted Pyrazolo-Pyrimidine Compounds as PIKfyve Inhibitors for Treating Neurological Diseases. | ACS Med Chem Lett | 2026 | 41704386 | PubTator, text mining | PubMed |
| PIKfyve is an essential component of the endolysosomal pathway within photoreceptors and the retinal pigment epithelium. | Exp Eye Res | 2026 | 41643834 | PubTator, text mining | PubMed |
| PIKfyve blockade exposes lysosomal vulnerability in myeloma. | Blood | 2026 | 41642608 | PubTator, text mining | PubMed |
| PtdIns(3,5)P2 is an endogenous ligand of STING in innate immune signalling. | Nature | 2026 | 41639454 | Swiss-Prot, curated | PubMed |
| PIKFYVE inhibition mitigates disease in models of diverse forms of ALS. | Cell | 2026 | 41581503 | PubTator, text mining | PubMed |
| 1-Phosphatidylinositol 3-Phosphate 5-Kinase Inhibition by Apilimod Promotes an Adipocyte-Like Vascular Smooth Muscle Cell Phenotype and Prevents Arterial Calcification. | Circ Res | 2026 | 41533526 | PubTator, text mining | PubMed |
| CD13 activation assembles phosphoinositide (PI) signaling complexes to regulate the actin cytoskeleton. | Sci Rep | 2026 | 41530254 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/200576/papers?page=2